P1229: PARP INHIBITORS ARE EFFECTIVE IN NATURAL KILLER/T CELL LYMPHOMA VIA THE EXPRESSION OF LMO2

por Wu, Jiazhuo, Zhang, Mingzhi
Publicado 2023

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

por Li, Hongwen, Li, Jing, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Song, Wenting, Li, Jiwei, Li, Zhaoming, Zhang, Mingzhi
Publicado 2023

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

por Wu, Jiazhuo, Shi, Cunzhen, Li, Hongwen, Song, Wenting, Huang, Shuo, Zhang, Jianxiang, Li, Wencai, Li, Zhaoming, Zhang, Mingzhi
Publicado 2023

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

por Li, Hongwen, Song, Wenting, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Li, Jiwei, Han, Lijuan, Zhang, Jianxiang, Li, Zhaoming, Li, Yong, Zhang, Mingzhi
Publicado 2023